EXPRESSION OF ER/PR/HER2, BASAL MARKERS AND ADHESION MOLECULES IN PRIMARY BREAST CANCER AND IN LYMPH NODES METASTASES: A COMPARATIVE IMMUNOHISTOCHEMICAL ANALYSIS

被引:16
作者
Adamczyk, Agnieszka [1 ]
Niemiec, Joanna [1 ]
Ambicka, Aleksandra [2 ]
Malecki, Krzysztof [3 ]
Wysocki, Wojciech H. [4 ]
Mitus, Jerzy [4 ]
Rys, Janusz [2 ]
机构
[1] Maria Sklodowska Curie Mem Inst Oncol, Dept Appl Radiobiol, Ctr Oncol, Cracow Branch, PL-31115 Krakow, Poland
[2] Maria Sklodowska Curie Mem Inst Oncol, Dept Tumor Pathol, Ctr Oncol, Cracow Branch, PL-31115 Krakow, Poland
[3] Univ Children Hosp Cracow, Dept Radiotherapy, Krakow, Poland
[4] Maria Sklodowska Curie Mem Inst Oncol, Dept Surg Oncol, Ctr Oncol, Cracow Branch, PL-31115 Krakow, Poland
关键词
primary breast tumour; lymph node metastasis; basal markers; adhesion molecules; IN-SITU HYBRIDIZATION; MATCHED PRIMARY; PRIMARY TUMORS; HER-2; OVEREXPRESSION; MAINTENANCE; PROGRESSION; SIGNATURE; CARCINOMA; THERAPY;
D O I
10.5114/PJP.2012.32769
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The immunophenotypic differences between primary and metastatic tumour cells could influence patient's treatment or/and the results of selected diagnostic procedures. That prompted us to investigate potential differences between primary tumours and corresponding synchronous lymph node metastases in the T >= 1/N + /M0 breast cancer patients. The investigated group consisted of 108 patients with invasive ductal breast cancer, who underwent radical surgery. The expression of ER, PR, HER2 as well as CK5/6, P-cadherin, EGFR and Ep-CAM was assessed immunohistochemically. Our data suggest that ER, PR, HER2, EGFR and CK5/6 are expressed conservatively, with some minor changes between primary tumour and simultaneous lymph node metastases. On the contrary, Ep-CAM and P-cadherin immunoreactivity in primary and metastatic cells varied significantly. This variation might exclude Ep-CAM and P-cadherin as potential diagnostic or therapeutic targets.
引用
收藏
页码:228 / 234
页数:7
相关论文
共 26 条
[1]  
Abolins A, 2011, POL J PATHOL, V62, P65
[2]   A Comparison of HER2/neu Gene Amplification and Its Protein Overexpression Between Primary Breast Cancer and Metastatic Lymph Nodes [J].
Aoyama, Kei ;
Kamio, Takako ;
Nishikawa, Toshio ;
Kameoka, Shingo .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 (07) :613-619
[3]   Comparison of hormonal receptor and HER-2 status between breast primary tumours and relapsing tumours: clinical implications of progesterone receptor loss [J].
Bogina, Giuseppe ;
Bortesi, Laura ;
Marconi, Marcella ;
Venturini, Marco ;
Lunardi, Gianluigi ;
Coati, Francesca ;
Massocco, Alberto ;
Manfrin, Erminia ;
Pegoraro, Cristina ;
Zamboni, Giuseppe .
VIRCHOWS ARCHIV, 2011, 459 (01) :1-10
[4]   HETEROGENEITY FOR ALLELIC LOSS IN HUMAN BREAST-CANCER [J].
CHEN, LC ;
KURISU, W ;
LJUNG, BM ;
GOLDMAN, ES ;
MOORE, D ;
SMITH, HS .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1992, 84 (07) :506-510
[5]   Comparison of Her-2, EGFR and Cyclin D1 in Primary Breast Cancer and Paired Metastatic Lymph Nodes: An Immunohistochemical and Chromogenic In Situ Hybridization Study [J].
Cho, Eun Yoon ;
Han, Jae Joon ;
Choi, Yoon-La ;
Kim, Kyoung-Mee ;
Oh, Young Lyun .
JOURNAL OF KOREAN MEDICAL SCIENCE, 2008, 23 (06) :1053-1061
[6]   Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis [J].
D'Andrea, Mario R. ;
Limiti, Maria R. ;
Bari, Mario ;
Zambenedetti, Pamela ;
Montagutti, Adriana ;
Ricci, Francesca ;
Pappagallo, Giovanni L. ;
Sartori, Donata ;
Vinante, Orazio ;
Mingazzini, Pietro L. .
BREAST CANCER RESEARCH AND TREATMENT, 2007, 101 (03) :279-284
[7]  
DAVIDOFF AM, 1991, CANCER RES, V51, P2605
[8]   A gene expression signature that defines breast cancer metastases [J].
Ellsworth, Rachel E. ;
Seebach, Jeff ;
Field, Lori A. ;
Heckman, Caroline ;
Kane, Jennifer ;
Hooke, Jeffrey A. ;
Love, Brad ;
Shriver, Craig D. .
CLINICAL & EXPERIMENTAL METASTASIS, 2009, 26 (03) :205-213
[9]   Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 [J].
Goldhirsch, A. ;
Wood, W. C. ;
Coates, A. S. ;
Gelber, R. D. ;
Thuerlimann, B. ;
Senn, H. -J. .
ANNALS OF ONCOLOGY, 2011, 22 (08) :1736-1747
[10]   Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma [J].
Gong, Y ;
Booser, DJ ;
Sneige, N .
CANCER, 2005, 103 (09) :1763-1769